Up-regulated thromboxane production in the rat liver with biliary obstruction does not contribute to promote hepatic injury

Shock

Volumn 29, Issue 6, 2008, Pages 688-691

  Yokoyama, Yukihiro ^a   Kawai, Toru ^a   Kawai, Satoru ^a   Kitagawa, Tomomi ^a   Watanabe, Katsutaka ^a   Kawai, Kiyotaka ^a   Nagino, Masato ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatic injury; In vivo; Portal hypertension; Thromboxane receptor antagonist; Thromboxane synthase inhibitor

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HYALURONIC ACID; OZAGREL; SODIUM CHLORIDE; THROMBOXANE A2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT LIGATION; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; GENE EXPRESSION; LIVER FUNCTION; LIVER INJURY; MALE; NONHUMAN; PERITONEAL CAVITY; RAT; UPREGULATION;

ALANINE TRANSAMINASE; ANIMALS; BILIRUBIN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYALURONIC ACID; HYDRAZINES; LIVER; LIVER DISEASES; MALE; METHACRYLATES; RATS; RATS, WISTAR; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE-A SYNTHASE; TIME FACTORS;

EID: 44449154697     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31815812ff     Document Type: Article

References (26)

1. Nakamura T, Kasai K, Sekiguchi Y, Banba N, Takahashi K, Emoto T, Hattori Y, Shimoda S: Elevation of plasma endothelin concentrations during endotoxin shock in dogs. Eur J Pharmacol 205:277-282, 1991.
2. Sonin NV, Garcia-Pagan JC, Nakanishi K, Zhang JX, Clemens MG: Patterns of vasoregulatory gene expression in the liver response to ischemia/reperfusion and endotoxemia. Shock 11:175-179, 1999.
3. Baveja R, Yokoyama Y, Korneszczuk K, Zhang JX, Clemens MG: Endothelin 1 impairs oxygen delivery in livers from LPS-primed animals. Shock 17:383-388, 2002.
4. Kawamura E, Yamanaka N, Okamoto E, Tomoda F, Furukawa K: Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusion injury. Hepatology 21:1138-1143, 1995.
5. Yokoyama Y, Baveja R, Sonin N, Nakanishi K, Zhang JX, Clemens MG: Altered endothelin receptor subtype expression in hepatic injury after ischemia/reperfusion. Shock 13:72-78, 2000.
6. Keller S, Karaa A, Paxian M, Clemens MG, Zhang JX: Inhibition of endothelin-1-mediated up-regulation of iNOS by bosentan ameliorates endotoxin-induced liver injury in cirrhosis. Shock 25:306-313, 2006.
7. Pannen BH, Schroll S, Loop T, Bauer M, Hoetzel A, Geiger KK: Hemorrhagic shock primes the hepatic portal circulation for the vasoconstrictive effects of endothelin-1. Am J Physiol Heart Circ Physiol 281:H1075-H1084, 2001.
8. Fisher RA, Robertson SM, Olson MS: Stimulation of glycogenolysis and vasoconstriction in the perfused rat liver by the thromboxane A2 analogue U-46619. J Biol Chem 262:4631-4638, 1987.
9. Temple GE, Cook JA, Wise WC, Halushka PV, Corral D: Improvement in organ blood flow by inhibition of thromboxane synthetase during experimental endotoxic shock in the rat. J Cardiovasc Pharmacol 8:514-519, 1986.
10. Iida J, Shimamura T, Suzuki T, Jin MB, Taniguchi M, Fukai M, Yokota R, Horiuchi H, Magata S, Kishida A, et al.: Inhibition of thromboxane A2 synthesis by OKY-046 attenuates ischemia and reperfusion injury of the liver. Transplant Proc 31:1061-1062, 1999.
11. Yokoyama Y, Xu H, Kresge N, Keller S, Sarmadi AH, Baveja R, Clemens MG, Zhang JX: Role of thromboxane A2 in early BDL-induced portal hypertension. Am J Physiol Gastrointest Liver Physiol 284:G453-G460, 2003.
12. Garcia-Pagan JC, Zhang JX, Sonin N, Nakanishi K, Clemens MG: Ischemia/reperfusion induces an increase in the hepatic portal vasoconstrictive response to endothelin-1. Shock 11:325-329, 1999.
13. Yokoyama Y, Baveja R, Kresge N, Sonin N, Nakanishi K, Zhang JX, Gitzelmann CA, Clemens MG: Endothelin receptor remodeling induces the portal venous hyper-response to endothelin-1 following endotoxin pretreatment. Shock 17:36-40, 2002.
14. Miller AM, Masrorpour M, Klaus C, Zhang JX: LPS exacerbates endothelin-1 induced activation of cytosolic phospholipase A2 and thromboxane A2 production from Kupffer cells of the prefibrotic rat liver. J Hepatol 46:276-285, 2007.
15. Haussinger D, Stehle T, Gerok W: Effects of leukotrienes and the thromboxane A2 analogue U-46619 in isolated perfused rat liver. Metabolic, hemodynamic and ion-flux responses. Biol Chem Hoppe Seyler 369:97-107, 1988.
16. Tran-Thi TA, Gyufko K, Reinke M, Decker K: Output and effects of thromboxane produced by the liver perfused with phorbol myristate acetate. Biol Chem Hoppe Seyler 369:1179-1184, 1988.
17. Kobayashi T, Esato K, Morita N, Noshima NS: Effects of thromboxane A2 synthesis inhibitor (OKY-046) on total liver ischemia in rats. Int Surg 81:115-118, 1996.
18. Sasaki T, Wakai S, Asano T, Takakura K, Sano K: Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581. J Neurosurg 57:74-82, 1982.
19. Suzuki S, Sano K, Handa H, Asano T, Tamura A, Yonekawa Y, Ono H, Tachibana N, Hanaoka K: Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. Neurol Res 11:79-88, 1989.
20. Shimada M, Matsumata T, Shirabe K, Sugimachi K: A thromboxane A2 synthetase inhibitor, OKY-046, reduces liver damage in hepatectomy. Surgery 114:993-995, 1993.
21. Bitterman H, Phillips GRI, Gragon G, Lefer AM: Potentiation of the protecting effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock. J Pharmacol Exp Ther 242:8-14, 1987.
22. Chang SW, Ohara N: Increased pulmonary vascular permeability in rats with biliary cirrhosis: role of thromboxane A2. Am J Physiol 264:L245-L252, 1993.
23. Ohara N, Voelkel NF, Chang SW: Tissue eicosanoids and vascular permeability in rats with chronic biliary obstruction. Hepatology 18:111-118, 1993.
24. Ackerman Z, Karmeli F, Amir G, Rachmilewitz D: Renal vasoactive mediator generation in portal hypertensive and bile duct ligated rats. J Hepatol 24:478-486, 1996.
25. Holt S, Marley R, Fernando B, Harry D, Anand R, Goodier D, Moore K: Acute cholestasisYinduced renal failure: effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney Int 55:271-277, 1999.
26. Kramer HJ: Impaired renal function in obstructive jaundice: roles of the thromboxane and endothelin systems. Nephron 77:1-12, 1997.